• By registering your interest to these sessions, you are agreeing for your information to be shared with the host.
• The host of the workshop reserves the right to refuse entry to any organisation that they feel may be competitive.
• You will receive confirmation of workshop registration via email prior to the event.

An exploration of how illicit compounding intersects with patent protections, market exclusivity, and the proposed EU pharma package revisions shaping the future of pharmaceutical innovation.

With the UPC now established, its impact on national litigation in key life sciences jurisdictions is becoming clearer. This session examines how the UPC’s decisions intersect with proceedings in the UK, France, Germany, the Netherlands, and the US. Speakers will explore recent cases, including BSH v. Electrolux and Fujifilm v. Kodak, assessing the reach of the UPC, divergence in substantive law, and the evolving balance between national and supranational enforcement.

• Discuss the impact of early UPC rulings on litigation strategies in the UK, France, Germany, and the Netherlands
• Analyse the long-arm reach of the UPC and lessons from cases such as BSH v. Electrolux and Fujifilm v. Kodak
• Compare how national courts and the UPC apply substantive law in overlapping disputes
• Evaluate strategic considerations for coordinating litigation in the UPC versus national and US courts

This 20 minute session unpacks the implications of G1/23 and explores how recent Board of Appeal decisions are reshaping product launch strategies in Europe. Gain practical insights into how these rulings affect exclusivity, regulatory interplay, and the timing of market entry.